Clinical Trials Directory

Trials / Completed

CompletedNCT05164146

The Comparison of Hypotension Incidence Between Remimazolam and Propofol in Hypertensive Patients Undergoing Neurosurgery

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
100 (actual)
Sponsor
Yonsei University · Academic / Other
Sex
All
Age
19 Years – 75 Years
Healthy volunteers
Accepted

Summary

This study aims to find an excellent drug in terms of hemodynamic stability when comparing the propofol and remifentanil with the combined use of remimazolam and remifentanil. When the mean blood pressure falls by 20% or more from the baseline mean blood pressure, it is considered hypotension, and a vasopressor such as ephedrine, phenylephrine, or norpin is used to control the blood pressure to within 20% of the baseline blood pressure. If the blood pressure increases by 20% or more above the baseline mean blood pressure, nicardipine infusion or remimazolam, propofol or remifentanil should be increased to control the blood pressure.

Conditions

Interventions

TypeNameDescription
DRUGpropofolduring the induction, remimazolam dose was controlled according to sedline (Psi target 40)
DRUGremimazolamDuring induction, remimazolam dose was controlled according to sedline (Psi target 40)

Timeline

Start date
2022-02-23
Primary completion
2022-08-10
Completion
2022-08-10
First posted
2021-12-20
Last updated
2022-11-07

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT05164146. Inclusion in this directory is not an endorsement.